Ditchcarbon
  • Contact
  1. Organizations
  2. ADMA Biologics, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

ADMA Biologics, Inc. Sustainability Profile

Company website

ADMA Biologics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of specialty biologics, particularly in the field of immunoglobulin therapies. ADMA focuses on providing innovative solutions for patients with immune deficiencies and other serious conditions, offering unique products such as its proprietary immunoglobulin, ASCENIV. This product stands out due to its high purity and specific formulation, catering to the needs of patients requiring immunotherapy. With a strong market position, ADMA Biologics has achieved significant milestones, including FDA approvals and partnerships that enhance its operational reach across North America. The company continues to drive advancements in the biologics sector, committed to improving patient outcomes through its specialised therapies.

DitchCarbon Score

How does ADMA Biologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

ADMA Biologics, Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

42%

Let us know if this data was useful to you

ADMA Biologics, Inc.'s reported carbon emissions

ADMA Biologics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a result, ADMA Biologics, Inc. does not appear to have established any formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data from ADMA Biologics, it is unclear how they plan to address climate change and carbon emissions in the future.

How Carbon Intensive is ADMA Biologics, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. ADMA Biologics, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is ADMA Biologics, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for ADMA Biologics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

ADMA Biologics, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

ADMA Biologics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare ADMA Biologics, Inc.'s Emissions with Industry Peers

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 13 hours ago

Baxter

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 2 days ago

Biotest

DE
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Bio Products Laboratory Ltd.

GB
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy